The Future of Weight Loss: What You Need to Know About the New Once-Daily Pills The next generation of UK weight loss medications: once-daily pills, MHRA licensing of the Wegovy pill, and how to check your eligibility through PrivateDoc
Yes, Mounjaro is a GLP-1 medication, but its more accurate to describe it as a dual GLP-1/GIP receptor agonist
Charles Barkley, an NBA Hall of Famer and current broadcaster, recently talked about the fact that he dropped a significant amount of weight after he started taking the medication Mounjaro
16(5): 555949.DOI: 10.19080/CRDOJ.2023.16.555949 Review Article Abstract Introduction Retatrutide for Treatment of Obesity Retatrutide for Treatment of Type 2 Diabetes Effects of Retatrutide on Cardiovascular Risk Factors Safety of Retatrutide Effect of Retatrutide on Heart Rate Advantages of Retatrutide Limitations of Retatrutide Conclusions and Current Needs References Abstract Retatrutide is a triple hormone agonist of the receptors of glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide (GIP) and glucagon that can be administered subcutaneously once a week
Since GLP1 Wegovy (semaglutide) and GIP Mounjaro (tirzepatide) medications are not approved specifically for smoking cessation, UK clinics, including Weight Medics, prescribe them for medical weight loss only
